Emergency Contraception in the US
The most significant recent event affecting emergency contraception actually occurred in December 2011, but reverberated throughout 2012. Since 2009, consumers aged 17 years and older were able to purchase emergency contraception without a prescription, albeit behind-the-counter. In February 2011, Teva submitted an application to the FDA requesting non-prescription access to its Plan B emergency contraception drug for those aged under 17 (competing products would remain behind-the-counter).
Euromonitor International's Emergency Contraception in USA report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2008-2012, allowing you to identify the sectors driving growth. Forecasts to 2017 illustrate how the market is set to change.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
Euromonitor International's Emergency Contraception in USA report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2008-2012, allowing you to identify the sectors driving growth. Forecasts to 2017 illustrate how the market is set to change.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
- Get a detailed picture of the Emergency Contraception market;
- Pinpoint growth sectors and identify factors driving change;
- Understand the competitive environment, the market’s major players and leading brands;
- Use five-year forecasts to assess how the market is predicted to develop.
Headlines
Trends
Competitive Landscape
Prospects
Category Data
Table 1 Sales of Emergency Contraception: Value 2007-2012
Table 2 Sales of Emergency Contraception: % Value Growth 2007-2012
Table 3 Emergency Contraception Company Shares by Value 2008-2012
Table 4 Emergency Contraception Brand Shares by Value 2009-2012
Table 5 Forecast Sales of Emergency Contraception: Value 2012-2017
Table 6 Forecast Sales of Emergency Contraception: % Value Growth 2012-2017
Executive Summary
Consumer Health Continues Its Upward Climb
Manufacturing Issues Worsen Rather Than Improve
Private Label Producers Capitalise on Branded Product Challenges
Retailers Aim To Play A Broader Role in Consumers' Lives
OTC Rebound Will Drive Higher Growth Over the Forecast Period
Key Trends and Developments
Continuing the Balance Between Industry and Government
Baby Boomers Impact on Vitamins and Dietary Supplements
Growth in Protein Is Bulking Up in Strength
Manufacturing Issues Continue To Plague Consumer Health
Regulatory Prospects Alter Strategic Landscape
Market Indicators
Table 7 Consumer Expenditure on Health Goods and Medical Services 2007-2012
Table 8 Life Expectancy at Birth 2007-2012
Market Data
Table 9 Sales of Consumer Health by Category: Value 2007-2012
Table 10 Sales of Consumer Health by Category: % Value Growth 2007-2012
Table 11 Consumer Health Company Shares 2008-2012
Table 12 Consumer Health Brand Shares 2009-2012
Table 13 Penetration of Private Label by Category 2007-2012
Table 14 Sales of Consumer Health by Distribution Format: % Analysis 2007-2012
Table 15 Sales of Consumer Health by Category and Distribution Format: % Analysis 2012
Table 16 Forecast Sales of Consumer Health by Category: Value 2012-2017
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2012-2017
Appendix
OTC Registration and Classification
Vitamins and Dietary Supplements Registration and Classification
Self-medication/self-care and Preventative Medicine
Switches
Summary 1 OTC: Switches 2010-2012
Sources
Summary 2 Research Sources
Trends
Competitive Landscape
Prospects
Category Data
Table 1 Sales of Emergency Contraception: Value 2007-2012
Table 2 Sales of Emergency Contraception: % Value Growth 2007-2012
Table 3 Emergency Contraception Company Shares by Value 2008-2012
Table 4 Emergency Contraception Brand Shares by Value 2009-2012
Table 5 Forecast Sales of Emergency Contraception: Value 2012-2017
Table 6 Forecast Sales of Emergency Contraception: % Value Growth 2012-2017
Executive Summary
Consumer Health Continues Its Upward Climb
Manufacturing Issues Worsen Rather Than Improve
Private Label Producers Capitalise on Branded Product Challenges
Retailers Aim To Play A Broader Role in Consumers' Lives
OTC Rebound Will Drive Higher Growth Over the Forecast Period
Key Trends and Developments
Continuing the Balance Between Industry and Government
Baby Boomers Impact on Vitamins and Dietary Supplements
Growth in Protein Is Bulking Up in Strength
Manufacturing Issues Continue To Plague Consumer Health
Regulatory Prospects Alter Strategic Landscape
Market Indicators
Table 7 Consumer Expenditure on Health Goods and Medical Services 2007-2012
Table 8 Life Expectancy at Birth 2007-2012
Market Data
Table 9 Sales of Consumer Health by Category: Value 2007-2012
Table 10 Sales of Consumer Health by Category: % Value Growth 2007-2012
Table 11 Consumer Health Company Shares 2008-2012
Table 12 Consumer Health Brand Shares 2009-2012
Table 13 Penetration of Private Label by Category 2007-2012
Table 14 Sales of Consumer Health by Distribution Format: % Analysis 2007-2012
Table 15 Sales of Consumer Health by Category and Distribution Format: % Analysis 2012
Table 16 Forecast Sales of Consumer Health by Category: Value 2012-2017
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2012-2017
Appendix
OTC Registration and Classification
Vitamins and Dietary Supplements Registration and Classification
Self-medication/self-care and Preventative Medicine
Switches
Summary 1 OTC: Switches 2010-2012
Sources
Summary 2 Research Sources
